Skip to main content
Betta Pharmaceuticals Co.,Ltd logo

Betta Pharmaceuticals Co.,Ltd — Investor Relations & Filings

Ticker · 300558 ISIN · CNE100002DD9 LEI · 8368009YF4Y6NC7HVB09 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,656 across all filing types
Latest filing 2019-04-19 AGM Information
Country CN China
Listing Shenzhen Stock Exchange 300558

About Betta Pharmaceuticals Co.,Ltd

https://www.bettapharma.com

Betta Pharmaceuticals Co.,Ltd. focuses on the research, development, and commercialization of innovative oncology medications. The organization specializes in targeted therapies, particularly for the treatment of lung cancer and other solid tumors. Its portfolio includes Icotinib, a small-molecule EGFR tyrosine kinase inhibitor, and Ensartinib, an ALK inhibitor designed for non-small cell lung cancer. The company operates a comprehensive R&D infrastructure dedicated to molecular biology, medicinal chemistry, and clinical development. By prioritizing precision medicine, the firm aims to deliver high-quality therapeutic solutions that address complex oncological challenges. Its pipeline encompasses a diverse range of candidates, including small molecules and biologics, aimed at improving patient outcomes through advanced scientific innovation.

Recent filings

Filing Released Lang Actions
关于举行2018年度网上业绩说明会的公告
AGM Information Classification · 95% confidence The document is a short announcement (594 characters) about the company holding an online performance explanation meeting for the 2018 annual report. It states that the full 2018 annual report has already been published on the official disclosure website. The document invites investors to participate in the online meeting to further understand the company's operations. There is no detailed financial data or the report itself included, only an announcement of the event related to the annual report. According to the MENU VS MEAL RULE, this is not the annual report itself but an announcement about a related event. Therefore, the appropriate classification is AGM Information (AGM-R) since it concerns an annual performance explanation meeting, which is similar to an AGM presentation or investor meeting about annual results.
2019-04-19 Chinese
关于公司及子公司申请综合融资额度及为融资额度内融资提供担保的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Betta Pharmaceuticals regarding the company's and its subsidiaries' application for a comprehensive financing quota and provision of guarantees within that financing quota. It details the board meeting approval, the subsidiaries involved, their financial status, and the purpose and scope of the financing and guarantees. There is no indication of this being a full financial report, audit report, or earnings release. Instead, it is a specific update on financing activities and guarantees related to capital structure and funding. The document length is about 5,177 characters, which is sufficient for a detailed announcement but not a full report. The content aligns with updates on company fundraising and financing activities, which fits the Capital/Financing Update category (CAP).
2019-04-15 Chinese
中国国际金融股份有限公司关于公司2018年度募集资金存放与使用情况的核查意见
Audit Report / Information Classification · 95% confidence The document is a detailed report from China International Capital Corporation Limited (the sponsor) regarding the 2018 annual verification of the deposit and use of raised funds by Betta Pharmaceuticals Co., Ltd. It includes extensive financial data on the amount of funds raised, their storage, management, usage, changes in investment projects, and compliance with relevant laws and regulations. The document also contains an auditor's verification opinion and sponsor's main verification work and opinions. The content focuses on the use and management of funds raised through an initial public offering and subsequent changes, which is typical of a specialized audit or verification report on fundraising activities rather than a full annual report or earnings release. The document length is 9577 characters, which is substantial and contains detailed financial tables and explanations. It is not a simple announcement or certification but a comprehensive audit-related report on fundraising usage. Therefore, the most appropriate classification is Audit Report / Information (AR). FY 2018
2019-04-15 Chinese
2018年度董事会工作报告
Management Reports Classification · 95% confidence The document is titled '2018 年度董事会工作报告' which translates to '2018 Annual Board of Directors Work Report'. It contains detailed financial data, management discussion and analysis, operational highlights, governance information, and future outlook. The content includes financial metrics, management commentary on performance, strategic initiatives, risk factors, and governance committee activities. The document is comprehensive and covers the company's yearly activities and financial performance. It is not a brief announcement or a presentation but a full report. The presence of detailed financial figures and management analysis indicates it is a Management Report (MDA) rather than a full Annual Report (10-K) or an Audit Report (AR). The document focuses on the board's work and management's discussion rather than the full audited financial statements typical of an Annual Report. Therefore, the most appropriate classification is Management Reports (MDA).
2019-04-15 Chinese
2018年度财务决算报告
Annual Report Classification · 95% confidence The document is titled '2018 年度财务决算报告' which translates to '2018 Annual Financial Settlement Report'. It contains detailed financial data for the full fiscal year 2018, including income statement figures, balance sheet data, cash flow statements, and key financial ratios. It also references an audit report issued by an accounting firm with an unqualified opinion, indicating this is a formal audited financial report. The document is over 6,800 characters, which is substantial and contains actual financial statements and analysis, not just an announcement or summary. The content aligns with a full annual report covering company activity and financial performance for the year. Therefore, the appropriate classification is Annual Report (10-K). FY 2018
2019-04-15 Chinese
2018年年度报告
Annual Report Classification · 100% confidence The document is titled '2018 年年度报告' which translates to '2018 Annual Report' and is issued by 贝达药业股份有限公司 (Betta Pharmaceuticals Co., Ltd.). It contains detailed sections typical of an annual report, including company overview, financial data, business summary, management discussion and analysis, governance, and financial statements. The document length is 15,000 characters, indicating a comprehensive report rather than a brief announcement. It includes financial figures for the year 2018, comparisons with previous years, and detailed business and industry analysis. There is no indication that this is merely an announcement or a certification. Therefore, this document fits the definition of an Annual Report (10-K). FY 2018
2019-04-15 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.